2026 Patients Prescription 
World of DTC Marketing
JULY 28, 2022
Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Nearly 9 in 10 older adults take prescription medication. Still, the pharma industry is fighting hard to keep it off the table.
World of DTC Marketing
FEBRUARY 22, 2021
billion by 2026. Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. This DTC is an embaressment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
OCTOBER 27, 2020
By 2026, national health expenditures will reach $5.7 Technology is increasingly enabling care to be delivered in these more accessible, convenient, lower-cost venues that can both engage people in their own care and drive health care costs down for all payors – especially for the consumer/patient as payor. gross domestic product.
pharmaphorum
JUNE 27, 2022
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026.
PM360
APRIL 7, 2023
Reduced patient out-of-pocket (OOP) costs in Part D have the potential to reduce beneficiary reliance on foundation support, with commensurate reductions in manufacturer donations required. The business-to-business market leaders must find new and creative ways to help patients receive their treatments.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. In both cases, a shift in formulary placement could lower prescription volumes and reduce member utilization.
Expert insights. Personalized for you.
256 
Let's personalize your content